Skip to main content Back to Top

Immune Checkpoint Inhibitors in Cancer Treatment: Overcoming Challenges in Identifying and Managing Immune-related Adverse Events

Broadcast Date: September 15, 2021


Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

In this podcast, expert faculty discuss the importance of timely identification and management of immune-related adverse events (irAEs) in patients being treated with immune checkpoint inhibitors, including commonly asked questions.

To learn more about this initiative visit


Ryan SullivanRyan Sullivan, M.D., is Attending Physician in the Division of Hematology/Oncology at Massachusetts General Hospital (MGH) in Boston, Massachusetts. He is board certified in Medical Oncology. At the MGH, Dr. Sullivan is Associate Director of the Melanoma Program and a member of the Termeer Center for Targeted Therapies. He is also Associate Professor of Medicine at Harvard Medical School. Dr. Sullivan is an active clinical and translational investigator. He has an interest in improving the prediction, through the development of blood-based biomarkers, and management of immune checkpoint inhibitor toxicity. Finally, he is a member of several national organizations including the American Society of Clinical Oncology, the American Association for Cancer Research, and the Society for the Immunotherapy of Cancer (SITC), and he serves as the Chair of the SITC Immunotherapy Resistance Committee Leadership Taskforce.


Jordan McPhersonJordan McPherson, Pharm.D., M.S., BCOP, is Oncology Clinical Pharmacist in the ambulatory solid tumor clinics at Huntsman Cancer Institute, an NCI-designated cancer hospital at University of Utah Health in Salt Lake City, Utah. Dr. McPherson specializes in the treatment of skin cancer using immunotherapy and other targeted therapies. He serves as a Panelist on the NCCN Guidelines for Management of Immune Checkpoint Inhibitor-Related Toxicities, and as Immediate Past President of the Utah Society of Health-System Pharmacists. Dr. McPherson’s research efforts are published in peer-reviewed journals, including the Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, and Pharmacotherapy.


Relevant Financial Relationship Disclosures

The following persons in control of this activity’s content have  relevant financial relationships:

Ryan Sullivan: Merck (research grants, consultant), BMS (consultant)

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As defined by the Standards of Integrity and Independence definition of ineligible company. All relevant financial relationships have been mitigated prior to the CPE activity.


The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Provided by ASHP
Supported by an educational grant from Merck